摘要
囊性纤维化是一种致命的常染色体隐性遗传病,会严重损害呼吸系统和消化系统。该病症是囊性纤维化跨膜电导调节(CFTR)蛋白异常引起的,CFTR是一种环磷腺苷依赖的上皮氯离子通道,也是ABC-转运蛋白超级家族的一种亚型。其主要在呼吸道、胰腺和肠上皮细胞的顶膜表达。单一氨基酸苯丙氨酸(Phe)的缺失是在CF患者中最常见的突变,并称为F508del-CFTR。通常情况下,在到达细胞膜之前,野生型CFTR就已经大大退化,而事实上F508del-CFTR从来没有到达细胞表面。我们最终的目的是校正CF患者中异常的CFTR蛋白。通过高通量筛选技术,最近已发现几种具有潜在药效的新化合物,它们能有效逆转分子的CF缺陷,并防止CF进一步恶化。S-亚硝基硫醇(SNOs)是个小分子,为天然存在的内源性细胞信号化合物,它与人类肺部疾病(包括CF)有潜在相关性。值得注意的是,有学者发现,在CF呼吸道的SNOs水平会减少。此前有报道,不同类型的SNOs,如谷胱甘肽和S-亚硝基谷胱甘肽乙酯,会促进人类呼吸道上皮细胞质膜CFTR的成熟和功能。然而,SNOs促进CFTR成熟的机制仍然不清楚。目前,有临床试验正在针对F508del-CFTR的新型矫正剂和增效剂的有效性和安全性进行研究。本文简介了关于最新CF治疗方法的知识。
关键词: 囊性纤维化跨膜电导调节因子(CFTR),囊性纤维化,分子治疗,S-亚硝基硫醇,S-亚硝基化
图形摘要
Current Drug Targets
Title:Novel Approaches for Potential Therapy of Cystic Fibrosis
Volume: 16 Issue: 9
Author(s): Victoria Sawczak, Paulina Getsy, Aliya Zaidi, Fei Sun, Khalequz Zaman and Benjamin Gaston
Affiliation:
关键词: 囊性纤维化跨膜电导调节因子(CFTR),囊性纤维化,分子治疗,S-亚硝基硫醇,S-亚硝基化
摘要: Cystic fibrosis (CF) is a lethal autosomal recessive disease that causes severe damage to the respiratory and digestive systems. It results from a dysfunctional CF Transmembrane Conductance Regulator (CFTR) protein, which is a cAMP- regulated epithelial chloride channel. CFTR is also a subtype of the ABC-transporter superfamily, and is expressed primarily in the apical membrane of epithelial cells in the airways, pancreas, and intestines. A single amino acid deletion of phenylalanine (Phe) is the most common mutation in CF patients known as F508del-CFTR. Normally, wild-type CFTR is largely degraded before reaching the cell membrane and F508del-CFTR virtually never reaches the cell surface. Ultimately, our goal is to correct dysfunctional CFTR proteins in CF patients. Via high-throughput screening techniques, several novel compounds for potential drugs effective in reversing the molecular CF defect and prohibiting further progression of CF have recently been discovered. S-nitrosothiols (SNOs) are small, naturally occurring endogenous cell signaling compounds, which have potential relevance to human lung diseases, including CF. Remarkably, researchers have found that the level of SNOs are reduced in the CF airway. It was previously reported that different types of SNOs, such as GSNO and S-nitrosoglutathione diethyl ester will increase CFTR maturation and function at the plasma membrane in human airway epithelial cells. The mechanisms by which SNOs improve CFTR maturation remain elusive. Currently, clinical trials are still investigating the effectiveness and safety of novel corrector and potentiator drugs for F508del- CFTR. This review article offers a summary of our knowledge on the most up-to-date CF therapies.
Export Options
About this article
Cite this article as:
Victoria Sawczak, Paulina Getsy, Aliya Zaidi, Fei Sun, Khalequz Zaman and Benjamin Gaston , Novel Approaches for Potential Therapy of Cystic Fibrosis, Current Drug Targets 2015; 16 (9) . https://dx.doi.org/10.2174/1389450116666150102113314
DOI https://dx.doi.org/10.2174/1389450116666150102113314 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Hot Topic: Glial Proteins and Peptides: Implications in Neuroinflammation)
Current Protein & Peptide Science Gastric Inhibitory Polypeptide and its Receptor are Expressed in the Central Nervous System and Support Neuronal Survival
Central Nervous System Agents in Medicinal Chemistry Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science Regulation of GABA Neurotransmission by Glutamic Acid Decarboxylase (GAD)
Current Pharmaceutical Design Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Vascular Endothelial Growth Factor Electro-Gene Therapy Improves Functional Outcome in a Mouse Model of ALS
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry The Nearest-Neighbor Effect on Random-Coil NMR Chemical Shifts Demonstrated Using a Low-Complexity Amino-Acid Sequence
Protein & Peptide Letters Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling
Current Alzheimer Research Biological and Pharmacological Effects of Gamma-oryzanol: An Updated Review of the Molecular Mechanisms
Current Pharmaceutical Design Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Non-Antidepressant Pharmacological Treatment of Obsessive Compulsive Disorder: A Comprehensive Review
Current Clinical Pharmacology Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Does Ceruloplasmin Defend Against Neurodegenerative Diseases?
Current Neuropharmacology